Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yarrow BioscienceYARW -2.78%13 Quick Ratio is 15.26 as of Jun. 2026, which is at its 10-year median of 15.26. GuruFocus rates YARW with a GF Score™ of 13/100. Among 1,407 Biotechnology companies, Yarrow Bioscience ranks better than 87.92% on this metric.
Yarrow Bioscience (NAS:YARW) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Yarrow Bioscience Quick Ratio Related Terms
Yarrow Bioscience Quick Ratio Historical Data
* Premium members only.
The historical data trend for Yarrow Bioscience's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience Quick Ratio Chart
Yarrow Bioscience Annual Data
Trend
Dec25
Quick Ratio
1.40
Yarrow Bioscience Quarterly Data
Jun25
Dec25
Mar26
Jun26
Quick Ratio
0.00
1.40
17.33
15.26
YARW vs CGTX, RANI, VRCA: Quick Ratio Comparison
For the Biotechnology subindustry, Yarrow Bioscience's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yarrow Bioscience Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Yarrow Bioscience's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Yarrow Bioscience's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience (YARW) has a Quick Ratio of 15.26 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Yarrow Bioscience and its competitors. This is near median its historical median of 15.26. Over the past decade, Yarrow Bioscience's Quick Ratio has ranged from 1.40 to 17.33. According to the industry distribution chart, Yarrow Bioscience ranks #170 out of 1407 companies in the Biotechnology industry, placing it in the top 12.1%.
Is Yarrow Bioscience's Quick Ratio too high?
Yarrow Bioscience's current Quick Ratio of 15.26 is near median its 10-year median of 15.26. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 17.33. The Biotechnology industry median Quick Ratio is 3.69. Yarrow Bioscience's value of 15.26 is 313.6% above this industry median. Based on the distribution chart, Yarrow Bioscience ranks #170 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's Quick Ratio compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #170 out of 1407 companies for Quick Ratio. This places Yarrow Bioscience in the top 12% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.69. Yarrow Bioscience's value of 15.26 is 313.6% above this benchmark. Historically, Yarrow Bioscience's own Quick Ratio has ranged from 1.40 to 17.33 over the past decade. While the company's 10-year median is 15.26 vs. the industry median of 3.69, Yarrow Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.69, based on 1,407 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yarrow Bioscience's current Quick Ratio of 15.26 is 313.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Yarrow Bioscience and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yarrow Bioscience's current Quick Ratio is 15.26, which is near median its own 10-year median of 15.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current Quick Ratio of 15.26. The current Quick Ratio is 15.26, which is near median its 10-year median of 15.26 and 313.6% above the Biotechnology industry median of 3.69. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current Quick Ratio is 15.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score
Get the complete analysis for YARW
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YARW has been successfully added to your 
